Model acetylcholinesterase‐Fc fusion glycoprotein biotechnology system for the manufacture of an organophosphorus toxicant bioscavenging countermeasure

Autor: Thomas G. Biel, Talia Faison, Alicia M. Matthews, Uriel Ortega‐Rodriguez, Vincent M. Falkowski, Edward Meek, Xin Bush, Matthew Flores, Sarah Johnson, Wells W. Wu, Mari Lehtimaki, Rong‐Fong Shen, Cyrus Agarabi, V. Ashutosh Rao, Janice E. Chambers, Tongzhong Ju
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Bioengineering & Translational Medicine, Vol 9, Iss 5, Pp n/a-n/a (2024)
Druh dokumentu: article
ISSN: 2380-6761
DOI: 10.1002/btm2.10666
Popis: Abstract Organophosphate (OP) toxicants remain an active threat to public health and to warfighters in the military. Current countermeasures require near immediate administration following OP exposure and are reported to have controversial efficacies. Acetylcholinesterase (AChE) fused to the human immunoglobulin 1 (IgG1) Fc domain (AChE‐Fc) is a potential bioscavenger for OP toxicants, but a reproducible AChE‐Fc biomanufacturing strategy remains elusive. This report is the first to establish a comprehensive laboratory‐scale bioprocessing strategy that can reproducibly produce AChE‐Fc and AChE(W86A)‐Fc which is a mutated AChE protein with reduced enzymatic activity. Characterization studies revealed that AChE‐Fc and AChE(W86A)‐Fc are N‐glycosylated dimeric fusion glycoproteins but only AChE‐Fc had the capability to bind to paraoxon (a model OP). This AChE‐Fc fusion glycoprotein bioprocessing strategy can be leveraged during industrial biomanufacturing development, while the research‐grade AChE‐Fc proteins can be used to determine the potential clinical relevance of the countermeasure against OP toxicants.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje